Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon
29 sept. 2022 08h19 HE
|
Biomerica, Inc.
Aware® is a simple at-home device to increase sensitivity in breast self-exams. About 80% of breast cancer is detected by women themselves who notice changes in their breast.EZ Detect™ is a simple...
Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer
30 août 2022 08h19 HE
|
Biomerica, Inc.
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development...
Biomerica Reports Fiscal 2022 Year End Results
29 août 2022 16h41 HE
|
Biomerica, Inc.
Revenues increase 162% for fiscal 2022 vs fiscal 2021 Revenues for fiscal Q4 2022 up 403% vs. fiscal Q4 2021 IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the...
Walmart to Begin Selling Biomerica’s Aware® Breast Self Exam
14 juil. 2022 08h19 HE
|
Biomerica, Inc.
Simple at-home device to increase sensitivity in breast self examsEarly detection of breast cancer saves livesBreast Cancer accounts for 1 in 3 new cases of cancer in women annually IRVINE,...
Biomerica to Participate at BTIG Biotech Conference
23 juin 2022 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person...
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
12 mai 2022 08h19 HE
|
Biomerica, Inc.
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human...
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
26 avr. 2022 08h19 HE
|
Biomerica, Inc.
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major...
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
14 avr. 2022 08h37 HE
|
Biomerica, Inc.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
08 févr. 2022 06h39 HE
|
Biomerica, Inc.
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
13 janv. 2022 08h19 HE
|
Biomerica, Inc.
Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon...